Cipla Stock News Today

Cipla is aiming to transition from a pure-play pharma company to an integrated health player, per analysts.

Sumeet Bagadia of Choice Broking has chosen Cipla as his ‘Valentines Day 2024 Pick’. Bagadia has recommended a ‘Buy’ on the pharma stock at ₹1,450 and up to ₹1,415 for a target price of ₹1,600 to ₹1,660.

Samina is the niece of Cipla non-executive chairman YK Hamied, and daughter of his brother and non-executive vice-chairman, MK Hamied. The company said she would continue as a non-executive director.

On Monday, Cipla reported a 31.8% year-on-year (YoY) jump in its October-December quarter consolidated net profit at Rs 1,056 crore. It was Rs 801 crore in the year-ago period.

The product, Vigabatrin for oral solution, USP 500mg, is used for the treatment of refractory complex partial seizures as adjunctive therapy in patients 2 years of age and older.

Cipla EU acquired an additional 15.1 percent of Cipla Maroc SA, Morocco, which is a JV between Cooper Pharma and Cipla EU.

According to analysts at HSBC, the USFDAs warning letter to Cipla hints at a lengthy resolution timeline and incremental costs

Stock Market Today - Ciplas Pithampur manufacturing facility receives warning letter. The facility remains important as exports of respiratory products such as Albuterol generics to the US are made form this facility.

Ciplas manufacturing facility received the VIA classification from the USFDA, meaning it is in a minimally acceptable state of compliance with regards to good manufacturing practice

Cipla Middle East Pharmaceuticals, UAE and Cipla Medica Pharmaceutical and Chemical Industries, Yemen have ceased to be subsidiaries of the pharma firm